This site uses cookies. By using this site you agree to receiving cookies. View Policy.

172%

Following research at Imperial College, we believe we’ve found a novel and effective treatment for relapsed/resistant cancer, targeting and killing cancer stem cells. With patents in place, we now need funding for the next phase: to complete lab-testing prior to clinical trials.

  • Novel and proprietary cancer treatment for relapsed/resistant cancer
  • Can kill cancer stem cells, one of the engines of cancer resistance and relapse
  • Strong scientific foundation developed at Imperial College, London
  • Commercially-experienced team with deep oncology knowledge

Idea

Cancer is a major cause of death, killing 9.6m people in 2018. We are developing a human protein-based therapeutic product, Syntana-4 (S-4), which inhibits cancer stem cells (CSC) - the growth engine of cancer.

If clinical trials are successful, S-4 could provide a desperately needed treatment option for many relapsed/resistant tumours with ‘Notch’ mutations.

The global cancer drug market was at ~$200bn in 2019. S-4 would initially target use for patients with relapsed prostate cancer, which caused 3.8% of global cancer deaths in 2018. Our research indicates that S-4 could help provide a solution to combat this deadly disease.

Alongside this, our research suggests S-4 will have low manufacturing costs, making it affordable, enabling ‘mass market’ sales strategy.

We have secured the rights and patents related to the delivery platform for CSC and other tissue, based on a cell-penetrating protein (ANTP) which can deliver drugs into the nucleus of cells.

We have raised £450k in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award and are now looking to raise to progress S-4 in collaboration with the University of Chicago’s current cancer stem cell therapeutics R&D program (partnership is pending signature).

Key milestones are to complete all steps to a phase II clinical trial, demonstrate clinical efficacy and then secure an exit through M&A.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Anastasis Biotec pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Anastasis Biotec has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.